✨ Free AI Report
Apollomics Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Apollomics Inc.
Company Research

Apollomics Inc.: Business Overview, Financials & Competitive Analysis

Apollomics is a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. The company's pipeline focuses on targeted the...

Analyst-debate audio for Apollomics Inc.

AskCyborg analysts argue the bull and bear cases for Apollomics Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Weak

Cyborg Score thesis

Early-stage oncology biotech with promising pipeline but significant near-term liquidity and regulatory listing...

Read the full analyst-debate transcript →
Industry Oncology Drugs
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Apollomics Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Apollomics Inc. Overview

Pro stress-test →

Apollomics is a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. The company's pipeline focuses on targeted therapies for difficult-to-treat cancers, with a lead program in vebreltinib for MET-altered non-small cell lung cancer and other solid tumors.

Strategic Profile

Pro stress-test →

The company's primary focus is to advance global development of vebreltinib for treatment of patients with c-MET alterations, with plans to submit an IND Application for accelerated approval in NSCLC in the first half of 2027. Beyond its lead c-Met inhibitor, the pipeline includes uproleselan for acute myeloid leukemia and three new immuno-oncology candidates (APL-501, APL-502, APL-801) with mono-specific and bi-specific antibodies.

Competitive Landscape

Pro stress-test →

Apollomics competes with other early-stage oncology biotech firms in targeted therapies for lung cancer and hematologic malignancies. Key competitors include Mersana Therapeutics, AnaptysBio, and Altimmune, though most peers are similarly capitalized. The company's c-Met and immuno-oncology focus positions it in crowded but high-value oncology segments where larger pharma and well-capitalized biotechs (e.g., Eli Lilly, Novartis, Roche) also compete.

Industry Context

Apollomics Inc. operates in Oncology Drugs.

Key facts

Founded: 2015 · Headquarters: Foster City, US · Revenue: $8.5M · Market cap: $32.2M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Apollomics Inc..

  • Lead program vebreltinib has dosed over 600 patients and 170 healthy volunteers in clinical trials, demonstrating clinical progress and potential de-risking ahead of 2027 IND submission
  • CEO bridge financing of $2.0M in March 2026 signals near-term cash constraints despite clinical advancement
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • June 2026Received Nasdaq deficiency notice regarding minimum market value requirement
  • April 2026Announced full year 2025 financial results; CEO provided $2.0M bridge financing for working capital
  • +1 moreTrack every material event for Apollomics Inc. as it happens. Explore monitoring →
Get alerted when Apollomics Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

c-Met inhibitorsLarge pharma with c-Met programs in oncology→Immuno-oncology antibodiesLeading oncology and immuno-oncology innovator→Early-stage AML therapiesClinical-stage biotech in hematologic malignancies→Oncology programsImmuno-oncology company with antibody programs→

Compare Apollomics Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Apollomics Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Apollomics Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Apollomics Inc. and its top competitor on Cyborg Score”
“What did Apollomics Inc. do this quarter?”
“Is Apollomics Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Apollomics Inc. do?+
Apollomics is a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. The company's pipeline focuses on targeted the...
What is Apollomics Inc.'s Cyborg Score?+
Apollomics Inc. has a Cyborg Score of 3/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Apollomics Inc.'s main competitors?+
Named competitors include c-Met inhibitors, Immuno-oncology antibodies, Early-stage AML therapies, Oncology programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Apollomics Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Apollomics Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Apollomics Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.